Razavi Seyed Mehrad, Hosseini Yasamin, Niknejad Amirhossein, Esmaealzadeh Niusha, Najafi Arab Zahra, Mavaddat Helia, Shahrahmani Fatemeh, Mortazavi Abolghasem, Momtaz Saeideh, Abdolghaffari Amir Hossein
Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., P. O. Box, Tehran, 19419-33111, Iran.
GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 10. doi: 10.1007/s00210-025-03868-8.
Traumatic brain injury (TBI) is a leading cause of death in accidents, sports, and warfare. Additionally, TBI imposes a significant financial burden on individuals and governments, necessitating substantial financial support. It also severely diminishes the quality of life for patients and their caregivers. TBI is consisted of two distinct phases: the primary and secondary phases. The primary phase consists of numerous events that occur immediately after the injury or concussion but the second phase takes times and include several of responsive cascades that human body express against TBI. After TBI incidence, several cellular and molecular pathways (inflammatory, apoptotic, anti-oxidant) will be dysregulated. Over the years, numerous therapeutic approaches have been implemented to treat this debilitating condition, aiming to alleviate its symptoms and complications, while enhancing patients' quality of life. Consequently, the search for more efficient with less adverse effects therapeutic methods remains a priority. One herbal medication that has recently garnered considerable attention is saffron. Data were collected from Scopus, Google Scholar, PubMed, and Cochrane Library for clinical, in vivo and in vitro studies published in English between 1992 and Jan 2025. Search terms included "TBI" OR "Traumatic brain injury" AND "Saffron" AND "Safranal" AND "Crocin" AND "Crocetin" AND "Kaempferol". The initial search yielded approximately 3,000 manuscripts. After screening and full-text evaluation, as detailed in the search methodology, ten experiments (in-vitro & in-vivo) were ultimately included. Saffron showed to modulate various signaling pathways and cytokines such as NF-kB, NLRP3, Nrf2, HO-1, Bcl2, and Bax, which will lead to the improvement of TBI sign and symptoms and increase the quality of life. It has been demonstrated that this compound could play a multifactorial role in TBI treatment such as reduction in inflammation, apoptosis, and oxidative stress, while modulating microglia activation. The findings suggest that saffron may play a pivotal role in treating TBI and mitigating its complications by regulating various pathophysiological pathways. However, more clinical trials are necessary to evaluate saffron's effectiveness in individuals diagnosed with TBI. Clinical trials should focus on various areas such as saffrons' safety profile, adverse effects, the exact mechanism of action, its' impact on acute and chronic TBI, rehabilitation, and long-term neuroprotection.
创伤性脑损伤(TBI)是事故、运动和战争中主要的死亡原因。此外,TBI给个人和政府带来了巨大的经济负担,需要大量的财政支持。它还严重降低了患者及其护理人员的生活质量。TBI由两个不同阶段组成:急性期和亚急性期。急性期由受伤或脑震荡后立即发生的众多事件组成,但亚急性期需要时间,包括人体对TBI产生的几种反应性级联反应。TBI发生后,一些细胞和分子途径(炎症、凋亡、抗氧化)将失调。多年来,已经实施了许多治疗方法来治疗这种使人衰弱的疾病,旨在减轻其症状和并发症,同时提高患者的生活质量。因此,寻找更有效且副作用更小的治疗方法仍然是当务之急。一种最近备受关注的草药药物是藏红花。从Scopus、谷歌学术、PubMed和考克兰图书馆收集了1992年至2025年1月期间以英文发表的临床、体内和体外研究的数据。搜索词包括“TBI”或“创伤性脑损伤”以及“藏红花”“藏红花醛”“藏花素”“藏红花酸”和“山奈酚”。初步搜索产生了大约3000篇手稿。按照搜索方法中详细说明的那样,经过筛选和全文评估,最终纳入了十项实验(体外和体内)。藏红花显示出可调节多种信号通路和细胞因子,如核因子κB、NLRP3、核因子E2相关因子2、血红素加氧酶-1、B细胞淋巴瘤-2和Bax,这将导致TBI体征和症状的改善,并提高生活质量。已经证明,这种化合物在TBI治疗中可能发挥多方面作用,如减轻炎症、凋亡和氧化应激,同时调节小胶质细胞的激活。研究结果表明,藏红花可能通过调节各种病理生理途径在治疗TBI和减轻其并发症方面发挥关键作用。然而,需要更多的临床试验来评估藏红花对诊断为TBI的个体的有效性。临床试验应关注多个领域,如藏红花的安全性、副作用、确切作用机制及其对急性和慢性TBI、康复和长期神经保护的影响。